BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Patrys Limited (PATZF.PK) Expands Clinical Trial to New Site in Queensland


9/19/2011 12:52:58 PM

Melbourne, Australia; 19 September, 2011: Patrys Limited (ASX: PAB; “the Company”), today announced the initiation of a second clinical centre, Princess Alexandra Hospital based in Queensland, in its Phase I clinical trial of anti-cancer antibody PAT-SM6 for the treatment of melanoma.

Princess Alexander Hospital joins the Royal Adelaide Hospital, which is currently recruiting the third group of patients. Significantly, no safety issues have been observed or reported for any patients treated, to date, with PAT-SM6. Additionally, recent analysis of tumour samples from two patients treated with PAT-SM6 found that the antibody had penetrated into the tumour biopsies, even though the doses were substantially below the anticipated therapeutic levels.

Dr Marie Roskrow, CEO said: “We have recently announced that the third cohort is open for recruitment, with an additional centre involved in the study this should enable us to advance the study quickly. As the trial progresses it is also important to have additional centres ready to assist in the next phase of testing for PAT-SM6.”

Associate Professor Mark Smithers, lead investigator for the trial at Princess Alexandra Hospital added: “We are pleased to support this trial at Princess Alexandra Hospital and offer patients a trial that is investigating a new treatment for the very difficult problem of recurrent melanoma.”

PAT-SM6 is a natural human antibody that has shown promise as a potential treatment for multiple types of cancer including melanoma. It is the first reported clinical product to target an important protein on the surface of cancer cells called GRP78 that plays a number of key roles in cancer cell survival, growth and metastasis.


Read at BioSpace.com


   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->